Prof Heinz Ludwig speaks to ecancer about his talk at IMW 2021 regarding vaccinations in myeloma including COVID-19.
Prof Ludwig begins by explaining the biology of the COVID-19 virus and its impact on myeloma patients. He mentions that higher mortality due to COVID-19 is seen amongst patients with increasing age and prior therapies. This mortality is also related to renal cancer, high-risk cytogenetics and morbidity.
Prof Ludwig discusses how important it is to prevent patients from contracting COVID-19. He then describes the types of vaccines currently available all over the world.
Prof Ludwig says that many myeloma patients respond well to the vaccine. However, those with ongoing disease or those who have received treatment with anti-bodies, PUMA, CAR T cell show a lower response rate.
Prof Ludwig concludes by discussing how can these high-risk patients be better vaccinated against COVID-19.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.